










*AI in Healthcare & Pharma Summit
November 18-19, 2025*

Application of AI/ML and Computer Vision in Drug Development

*Wei-Ting Liu, PhD.
Associate Director, Data Science
Pharmaceutical Development and Manufacturing
Gilead Science*



Gilead utilizes a variety of image techniques to support drug development and characterization

Material	Technique	Example Image	Material	Technique	Example Image
Lyocake	SEM/CT		Drug Substance	IR	
Depot	CT/Optical Microscopy/SEM		Tablet	Raman	
Tissues	Raman/FTIR/Optical Microscopy		Tablet	Micro CT	
			Drug Substance	SEM/Optical	



Apply AI/ML and Computer Vision to analyze image data and support quantitative decision making






Computer Vision in Drug Development and Characterization

Dry Powder

Morphological profiling of dry powder from SEM images





Advanced Segmentation



Morphology characterization and Statistical analysis to compare lots

Drug Product

Correlating 3D microstructural properties (coating, porosity) with critical quality attributes





Coating analysis

Chu et al., Simulation-based content uniformity engineering for drug development and manufacturing, International Journal of Pharmaceutics, 2025

Tin et al., A Nondestructive Image-Based Microstructural Characterization of Solid Oral Dosage Forms. IS&T International Symposium on Electronic Imaging 2025

Ex vivo

Depot characterization for formulation and device screening



Wei-Ting Liu, Nicole Tin, Robert Gresham, Pallavi Pawar, Tyler Novak, Remus Osan. to be published





Apply AI/ML and Computer Vision for Long-Acting Injectable Depot Characterization and Tissue Interactions



Long-Acting Therapies Are Established as Providing Novel Benefits

Long Acting Injectable (LAI) formulations provide stable therapeutic drug exposure for prolonged periods of time (i.e., weeks to several months) after administering a single dose.



IM: Intramuscular, SC: Subcutaneous

Examples

- **Olanzapine Pamoate**- Once 2-4 weeks (1-2.7 mL), IM for Schizophrenia
- **Lenacapavir**- Once in 6 months (1.5 mL X 2), SC for HIV



Enhance patient adherence to treatment, improve efficacy

Antiretroviral therapies have progressed to a one pill regimen, but treatment persistence remains an issue




After 1 Year



40%-50% of chronic therapy patients stopped taking their medication (persistence)






35% drop in patients who correctly dosed each day (adherence)
Coy, K *JIAS* (2019)




Ex vivo porcine tissue models are physiologically similar to human and μ CT can visualize deposition of viscous LAI

For long acting injectables, the evaluation of formulation impact takes much longer than conventional injectables. Physiologically representative *in silico* models are essential to understand how formulations affect depot formation and the subsequent pharmacokinetics.



Apply AI/ML in 3D Analysis on Depot Geometry and Tissue Interactions



- Perform 3D analysis of depot geometry and dissolution simulation to support decision-making for screening and testing new formulations



Data Preprocessing and AI-assisted Labeling to Prepare Training dataset

Histogram equalization: improves the contrast in an image, stretch out the intensity range via mapping to a more uniform distribution



Raw image



Histogram
equalization



Enhanced image





Prepare
training data




AI assisted
+ manual
adjustments



Labeled training image



AI/ML model building and digital twins allows investigating depot morphology and extract key attributes




Use Model to
annotate full data
(400 slices)



From 3D depot geometry to drug release rates

- Develop computational models to estimate drug release based on the 3D geometry



In silico modeling to predict drug dissolution and release rate

Conclusion



AI and deep learning algorithms efficiently segment μ CT scanned LAI depots and dissolution models are developed to predict drug release profile



This model is broadly applicable to high viscosity LAI compounds, and we believe that this predictive model can abbreviate clinical trial requirements and accelerate transformative drug products to patients.

Acknowledgment

Analytical Development and Operations

- Remus Osan
- Chris Foti
- Nicole Tin
- Krutika Harish Jain
- Analytical Science Team

Formulation and Process Development

- Pallavi Pawar

Technical Development Strategy and Operations

- Joanna Koziara

Device, Packaging and Process

- Robert Gresham
- Tyler Novak
- Monica Swinney

AI IN HEALTHCARE & PHARMA SUMMIT

AI in Healthcare & Pharma Summit

NOVEMBER 18-19, 2025





Thank You